- Home
- NGNE vs MEC Comparison
NGNE vs MEC Comparison
Compare NGNE & MEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- MEC
- Stock Information
- Founded
- NGNE 2003
- MEC 1945
- Country
- NGNE United States
- MEC United States
- Employees
- NGNE N/A
- MEC N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- MEC Industrial Specialties
- Sector
- NGNE Health Care
- MEC Industrials
- Exchange
- NGNE Nasdaq
- MEC Nasdaq
- Market Cap
- NGNE 325.3M
- MEC 329.4M
- IPO Year
- NGNE N/A
- MEC 2019
- Fundamental
- Price
- NGNE $20.51
- MEC $14.49
- Analyst Decision
- NGNE Strong Buy
- MEC Strong Buy
- Analyst Count
- NGNE 7
- MEC 3
- Target Price
- NGNE $41.86
- MEC $21.33
- AVG Volume (30 Days)
- NGNE 123.0K
- MEC 167.2K
- Earning Date
- NGNE 08-11-2025
- MEC 08-05-2025
- Dividend Yield
- NGNE N/A
- MEC N/A
- EPS Growth
- NGNE N/A
- MEC 64.18
- EPS
- NGNE N/A
- MEC 0.86
- Revenue
- NGNE N/A
- MEC $524,606,000.00
- Revenue This Year
- NGNE N/A
- MEC $3.31
- Revenue Next Year
- NGNE N/A
- MEC $13.33
- P/E Ratio
- NGNE N/A
- MEC $16.89
- Revenue Growth
- NGNE N/A
- MEC N/A
- 52 Week Low
- NGNE $6.88
- MEC $11.72
- 52 Week High
- NGNE $74.49
- MEC $23.02
- Technical
- Relative Strength Index (RSI)
- NGNE 47.72
- MEC 42.04
- Support Level
- NGNE $18.94
- MEC $13.10
- Resistance Level
- NGNE $21.59
- MEC $15.14
- Average True Range (ATR)
- NGNE 1.40
- MEC 0.94
- MACD
- NGNE -0.26
- MEC -0.16
- Stochastic Oscillator
- NGNE 32.30
- MEC 43.30
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About MEC Mayville Engineering Company Inc.
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, power sports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly and logistic services.